VanEck Biotech ETF (NASDAQ:BBH) Hits New 1-Year High – Should You Buy?

VanEck Biotech ETF (NASDAQ:BBH)’s stock price hit a new 52-week high during trading on Thursday. The company traded as high as $247.83 and last traded at $247.7640, with a volume of 5,352 shares traded. The stock had previously closed at $241.07.

VanEck Biotech ETF Price Performance

The company has a 50 day moving average price of $235.08 and a 200 day moving average price of $207.96.

Institutional Trading of VanEck Biotech ETF

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Focus Financial Network Inc. bought a new stake in VanEck Biotech ETF during the 3rd quarter worth about $240,000. BigSur Wealth Management LLC acquired a new position in VanEck Biotech ETF during the 3rd quarter valued at about $126,000. Value Investment Professionals LLC acquired a new position in VanEck Biotech ETF during the 3rd quarter valued at about $333,000. Hummer Financial Advisory Services Inc bought a new position in shares of VanEck Biotech ETF in the 3rd quarter valued at about $345,000. Finally, Farther Finance Advisors LLC bought a new position in shares of VanEck Biotech ETF in the 3rd quarter valued at about $123,000. 32.05% of the stock is currently owned by institutional investors and hedge funds.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.